Shots: Hologic to acquire Focal for its BioZorb marker, an implantable 3D marker helping surgeons to overcome challenges in breast conserving surgery, or lumpectomy used to mark tumor excision site The acquisition on focus on treating breast cancer patients by improving Qol with 3D indicator at surgical site The US FDA has already granted 510(k) […]Read More
Tags : BioZorb
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US